Synthetic antibodies show efficacy against bunyaviruses, study finds
Having developed synthetic antibodies made of VHH complexes, researchers showed that these could be used to combat bunyaviruses successfully.
List view / Grid view
Having developed synthetic antibodies made of VHH complexes, researchers showed that these could be used to combat bunyaviruses successfully.
The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
Professor Yehuda Shoenfeld suggests hyperferritinaemia, a condition caused by high ferritin levels, may be causing the severe COVID-19 symptoms.
Using an antibody to a particular malaria protein called PfGARP, researchers have developed a new strategy for designing a malaria vaccine.
Researchers discovered the monoclonal antibodies of a convalescent Marburg infection patient bound to the glycoprotein and combatted infection in two novel ways.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
Researchers who developed modified proteins say this could be used in the fight against COVID-19, by tackling cytokine storms.
An international consortium suggest that the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS), could be caused by Neutrophil Extracellular Traps (NETs).
The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
Researchers working on related coronaviruses SARS and MERS have identified the membrane fusion peptide on the Spike protein as a possible drug target for SARS-CoV-2, the virus causing COVID-19.
The vaccine candidate protected all murine models from a lethal MERS infection and could also be effective against the SARS-CoV-2 virus causing COVID-19.
Researchers have created a new kind of immunotherapy using the interleukin-27 (IL-27) cytokine to effectively combat tumours in vitro and in vivo.